RedHill Biopharma (RDHL) Tops Q3 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights
November 19, 2019 7:00 AM ESTKey Highlights:
U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to commercialize Aemcolo® in the U.S. for travelers diarrhea  Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of Aemcolo® and Talicia® in Q4/2019 and Q1/2020, respectively  Debt-free... More